查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1492648

巨细胞病毒检测市场：依测试类型、样本类型、使用者群体、最终用途 – 2024-2030 年全球预测

Cytomegalovirus Tests Market by Test Type (Antigenemia Tests, Culture Tests, Molecular Tests), Sample Type (Blood Samples, Urine Samples), User Group, End Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

巨细胞病毒检测市场规模预计2023年为6.4128亿美元，2024年将达到6.8078亿美元，预计2030年将达到10.2506亿美元，复合年增长率为6.93%。

巨细胞病毒(CMV) 检测是一种检测个体体内是否有巨细胞病毒的医学检测。巨细胞病毒是疱疹病毒科中常见的病毒，可以感染所有年龄层的人。健康人即使被感染通常也不会表现出任何症状，甚至可能没有意识到自己被感染，但鉅细胞病毒对于免疫力较弱的人来说可能很严重，对于出生前感染的新生儿可能会造成严重的健康风险。社会和临床对 CMV 影响的认识不断提高，尤其是对孕妇和免疫力缺乏患者的影响，正在推动对 CMV 检测的需求。此外，随着全球器官移植数量的增加，对准确 CMV 检测以确保移植安全和成功的需求也随之增加。然而，高成本和获得先进测试设施的机会有限可能会阻碍市场成长，特别是在新兴市场。此外，各国复杂的监管环境和不同的报销政策可能会成为采用先进 CMV 测试技术的障碍。此外，分子诊断的创新以及更快、更准确的测试方法的开拓也促进了市场的成长。利用次世代定序仪和基于 CRISPR 的技术进行 CMV 检测有可能提高灵敏度、特异性和成本效益。

主要市场统计
基准年[2023] 64128万美元
预计年份 [2024] 68078万美元
预测年份 [2030] 1,025,060,000 美元
复合年增长率（%） 6.93%

区域洞察

美洲，特别是美国和加拿大，构成了巨细胞病毒（CMV）检测的重要市场。医疗基础设施的改善、医疗成本的上升以及人们对鉅细胞病毒感染疾病早期诊断和治疗重要性的认识不断提高，正在促进这些国家的市场成长。该地区消费者的需求是由对高标准医疗保健实践和先进诊断解决方案的需求所驱动的。政府和私营部门支持的持续研究和开发工作旨在提高 CMV 测试的准确性和可及性。欧盟 (EU) CMV 检测市场的特点是严格的监管标准以及病患照护和安全的重要原则。欧盟国家受益于完善的医疗保健系统和公民的高度健康意识。欧盟境内的消费者需要安全、经过验证且具成本效益的测试选项。中东拥有阿联酋和沙乌地阿拉伯等富裕国家，医疗保健产业不断发展，对医疗保健基础设施和服务的投资不断增加。相反，非洲面临医疗设施有限和缺乏意识等挑战。由于医疗支出增加、经济成长和庞大的患者数量，亚太地区正迅速崛起为重要的 CMV 检测市场。中国和印度人口众多，对负担得起的医疗保健解决方案有很高的需求，包括鉅细胞病毒等感染疾病的诊断测试。日本以其先进的医疗保健系统和技术创新而闻名，表现出对高品质、精确诊断的偏好。这些国家的研究和开发倡议专注于创建满足当地需求的具有成本效益和高效的诊断解决方案。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在巨细胞病毒测试市场的定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对巨细胞病毒检测市场中供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该行业竞争性质的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对巨细胞病毒检测市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地 CMV 感染盛行率上升
      • 提高公众和临床对 CMV 影响的认识
      • 全球肝臟移植数量不断增加
    • 抑制因素
      • 成本高且先进测试设施的使用机会有限
    • 机会
      • 分子诊断创新和更快、更准确检测方法的开发
      • 使用次世代定序和基于 CRISPR 的技术进行 CMV 检测
    • 任务
      • 复杂的法规环境和特定国家的报销政策
  • 市场区隔分析
    • 测试类型：在提高分子测试（尤其是聚合酵素链锁反应）的灵敏度和特异性方面不断取得进展
    • 最终用途：研究机构更多地使用巨细胞病毒检测来开发疫苗
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章按测试类型分類的巨细胞病毒测试市场

  • 抗原血症测试
  • 文化测试
  • 分子检测
  • 血清学检测

第七章依样本类型分類的巨细胞病毒检测市场

  • 血液样本
  • 尿液样本

第八章按使用者群组分類的巨细胞病毒检测市场

  • 免疫力缺乏者
  • 新生
  • 怀孕的女人

第九章巨细胞病毒检测市场：依最终用途分类

  • 诊断实验室
  • 医院/诊所
  • 调查机构

第10章美洲巨细胞病毒检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太鉅巨细胞病毒检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲巨细胞病毒检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准扩大使用默克公司的 PREVYMIS 来预防高风险肾移植患者的 CMV 感染
    • Diasolin 在先天性 CMV 检测方面取得突破
  • 战略分析和建议

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-6B0EA07975A5

[184 Pages Report] The Cytomegalovirus Tests Market size was estimated at USD 641.28 million in 2023 and expected to reach USD 680.78 million in 2024, at a CAGR 6.93% to reach USD 1,025.06 million by 2030.

Cytomegalovirus (CMV) tests are medical examinations used to detect the presence of the cytomegalovirus in an individual's body. The cytomegalovirus is a common virus that belongs to the herpesvirus family and can infect people of all ages. While healthy individuals often show no symptoms upon infection and may not be aware they have been infected, CMV can pose significant health risks to people with weakened immune systems and to newborns if they are infected before birth. Growing public and clinical awareness regarding the implications of CMV, especially in pregnant women and immunocompromised patients, drives the demand for CMV testing. Additionally, as the number of organ transplants increases globally, the need for precise CMV testing escalates to ensure safe and successful transplant outcomes. However, high costs and limited access to sophisticated testing facilities can impede market growth, particularly in developing regions. Moreover, complex regulatory landscapes and varying reimbursement policies across countries can create hurdles in the adoption of advanced CMV testing technologies. Furthermore, innovations in molecular diagnostics and the development of faster, more accurate testing methods contribute to market growth. Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection offers the potential to improve sensitivity, specificity, and cost-effectiveness.

KEY MARKET STATISTICS
Base Year [2023] USD 641.28 million
Estimated Year [2024] USD 680.78 million
Forecast Year [2030] USD 1,025.06 million
CAGR (%) 6.93%

Regional Insights

The Americas, particularly the United States and Canada, represent a significant market for cytomegalovirus (CMV) tests. Enhanced healthcare infrastructure, high healthcare spending, and an increasing awareness of the significance of early diagnosis and treatment of CMV infections contribute to the market's growth in these countries. The consumer need in the region is driven by a high standard of healthcare practices and a demand for advanced diagnostic solutions. Ongoing research and development activities, supported by both government and private sectors, aim to improve the accuracy and accessibility of CMV testing. In the European Union, the market for CMV tests is characterized by stringent regulatory standards and a vital principle on patient care and safety. EU countries benefit from a well-established healthcare system and high health awareness among the population. The consumer need within the EU is for safe, validated, and cost-effective testing options. The Middle East, with its wealthier nations like the UAE and Saudi Arabia, is witnessing a growing healthcare sector with increasing investments in healthcare infrastructure and services. Conversely, Africa faces challenges such as restricted access to healthcare facilities and an insufficiency of awareness. The APAC region is rapidly emerging as a significant CMV test market driven by increasing healthcare expenditure, economic growth, and a huge patient population. China and India, with their vast populations, have a high demand for affordable healthcare solutions, including diagnostic tests for infectious diseases such as CMV. Japan, known for its advanced healthcare system and technological innovation, demonstrates a preference for high-quality and precision diagnostics. Research and development initiatives in these countries are focused on creating cost-effective and efficient diagnostic solutions to meet local needs.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Cytomegalovirus Tests Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of CMV infections across the globe
      • Growing public and clinical awareness regarding the implications of CMV
      • Increasing number of liver transplant globally
    • Market Restraints
      • High cost and limited access to sophisticated testing facilities
    • Market Opportunities
      • Innovations in molecular diagnostics and the development of faster, more accurate testing methods
      • Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection
    • Market Challenges
      • Complex regulatory landscapes and varying reimbursement policies across countries
  • Market Segmentation Analysis
    • Test Type: Ongoing advancements in molecular tests especially particularly polymerase chain reaction to improve sensitivity and specificity
    • End Use: Increasing utilizations of cytomegalovirus tests by research institutions for vaccine development
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cytomegalovirus Tests Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cytomegalovirus Tests Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves Expanded Use of PREVYMIS by Merck to Prevent CMV in High-Risk Kidney Transplant Recipients

The U.S. Food and Drug Administration (FDA) has recently approved a new application for Merck's antiviral drug, Prevymis (letermovir), to include its use in preventing cytomegalovirus (CMV) disease among adult recipients of kidney transplants with high-risk. Prevymis aims to significantly reduce the risk of viral infection and associated complications by preventing the activation of the virus in patients with weakened immune systems post-transplant. This decision by the FDA was supported by robust clinical trials that demonstrated the drug's effectiveness and safety in this new patient demographic, paving the way for its broader use in transplant medicine. [Published On: 2023-06-06]

DiaSorin's Breakthrough in Congenital CMV Detection

DiaSorin, an Italian diagnostic firm, announced its achievement in gaining 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative Simplexa Congenital CMV Direct kit. This cutting-edge diagnostic tool marks a significant milestone as the first FDA-approved test to detect cytomegalovirus (CMV) DNA in both saliva and urine samples of newborns aged 21 days or younger. Integrating this test into the Liaison MDx instrument facilitates swift and accurate diagnoses of congenital CMV, enabling timely interventions and treatments. [Published On: 2022-11-09]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cytomegalovirus Tests Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cytomegalovirus Tests Market, highlighting leading vendors and their innovative profiles. These include Abbexa Ltd., Abbott Laboratories, Accubiotech Co., Ltd, AdvaCare Pharma USA, Agilent Technologies, Inc., Atlas Medical GmbH, Bio-Rad Laboratories, Inc., Biogenix Inc. Pvt. Ltd., CLONIT srl, Creative Diagnostics, CTK Biotech Inc. by SSI Diagnostica A/S, Diasorin S.p.A., Elabscience Bionovation Inc., F. Hoffmann-La Roche Ltd., Hangzhou Realy Tech Co., Ltd., Intec Products, Inc., IQ Products B.V., Jiangsu Macro & Micro-Test Med-Tech Co., Ltd., Meridian Bioscience, Inc. by SD Biosensor, and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Cytomegalovirus Tests Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Test Type
    • Antigenemia Tests
    • Culture Tests
    • Molecular Tests
    • Serological Tests
  • Sample Type
    • Blood Samples
    • Urine Samples
  • User Group
    • Immunocompromised Individuals
    • Newborns
    • Pregnant Women
  • End Use
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Research Institutions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of CMV infections across the globe
      • 5.1.1.2. Growing public and clinical awareness regarding the implications of CMV
      • 5.1.1.3. Increasing number of liver transplant globally
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and limited access to sophisticated testing facilities
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in molecular diagnostics and the development of faster, more accurate testing methods
      • 5.1.3.2. Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscapes and varying reimbursement policies across countries
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Test Type: Ongoing advancements in molecular tests especially particularly polymerase chain reaction to improve sensitivity and specificity
    • 5.2.2. End Use: Increasing utilizations of cytomegalovirus tests by research institutions for vaccine development
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Cytomegalovirus Tests Market, by Test Type

  • 6.1. Introduction
  • 6.2. Antigenemia Tests
  • 6.3. Culture Tests
  • 6.4. Molecular Tests
  • 6.5. Serological Tests

7. Cytomegalovirus Tests Market, by Sample Type

  • 7.1. Introduction
  • 7.2. Blood Samples
  • 7.3. Urine Samples

8. Cytomegalovirus Tests Market, by User Group

  • 8.1. Introduction
  • 8.2. Immunocompromised Individuals
  • 8.3. Newborns
  • 8.4. Pregnant Women

9. Cytomegalovirus Tests Market, by End Use

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Research Institutions

10. Americas Cytomegalovirus Tests Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cytomegalovirus Tests Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cytomegalovirus Tests Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves Expanded Use of PREVYMIS by Merck to Prevent CMV in High-Risk Kidney Transplant Recipients
    • 13.3.2. DiaSorin's Breakthrough in Congenital CMV Detection
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CYTOMEGALOVIRUS TESTS MARKET RESEARCH PROCESS
  • FIGURE 2. CYTOMEGALOVIRUS TESTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CYTOMEGALOVIRUS TESTS MARKET DYNAMICS
  • FIGURE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CYTOMEGALOVIRUS TESTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. CYTOMEGALOVIRUS TESTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CYTOMEGALOVIRUS TESTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CULTURE TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CULTURE TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOCOMPROMISED INDIVIDUALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOCOMPROMISED INDIVIDUALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEWBORNS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEWBORNS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 327. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 328. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 335. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 336. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2024-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
  • TABLE 344. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 346. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE,